{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:22:36Z","timestamp":1792408956626,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23ck0106655h0003"],"award-info":[{"award-number":["23ck0106655h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JapicCTI-194851"],"award-info":[{"award-number":["JapicCTI-194851"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.esmoop.2024.103642","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T11:49:52Z","timestamp":1721130592000},"page":"103642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-5923","authenticated-orcid":false,"given":"S.","family":"Niho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Toyozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Daga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-2505","authenticated-orcid":false,"given":"T.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sakakibara-Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-3349","authenticated-orcid":false,"given":"M.","family":"Morise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kodani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-357X","authenticated-orcid":false,"given":"K.","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-6984","authenticated-orcid":false,"given":"S.","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.esmoop.2024.103642_bib1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nrc3612","article-title":"Tyrosine kinase gene rearrangements in epithelial malignancies","volume":"13","author":"Shaw","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"10.1016\/j.esmoop.2024.103642_bib2","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-12-2851","article-title":"Molecular pathways: ROS1 fusion proteins in cancer","volume":"19","author":"Davies","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103642_bib3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2024.103642_bib4","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.103642_bib5","article-title":"Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer","volume":"2017","author":"Gainor","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.103642_bib6","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.esmoop.2024.103642_bib7","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103642_bib8","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103642_bib9","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2017.75.5587","article-title":"Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103642_bib10","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2024.103642_bib11","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103642_bib12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103642_bib13","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","article-title":"Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSe phase II trial","volume":"30","author":"Moro-Sibilot","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103642_bib14","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jtho.2019.03.020","article-title":"Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial","volume":"14","author":"Michels","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2024.103642_bib15","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1158\/1078-0432.CCR-19-0994","article-title":"Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a phase II, prospective, multicenter, two-arms trial","volume":"25","author":"Landi","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103642_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers - biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103642_bib17","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103642_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103642_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jtho.2020.11.004","article-title":"Brigatinib in Japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase inhibitors: outcomes of the phase 2 J-ALTA trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103642_bib20","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1111\/cas.15888","article-title":"Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: final results of the phase 2 J-ALTA trial","volume":"114","author":"Yoshida","year":"2023","journal-title":"Cancer Sci"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103642_bib21","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-22-1749","article-title":"A\u00a0large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid)","volume":"29","author":"Sugimoto","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103642_bib22","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","article-title":"Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer","volume":"27","author":"Lin","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103642_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2022-1059","article-title":"TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors","volume":"19","author":"Nagasaka","year":"2023","journal-title":"Future Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292401411X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292401411X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:49:10Z","timestamp":1778834950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292401411X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S205970292401411X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103642","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103642"}}